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Monoamine neurotransmitter transporters for norepineph-
rine (NE), dopamine and serotonin are important targets for
antidepressants and analgesics. The conopeptide -MrIA is a
noncompetitive and highly selective inhibitor of the NE trans-
porter (NET) and is being developed as a novel intrathecal anal-
gesic. We used site-directed mutagenesis to generate a suite of
mutated transporters to identify two amino acids (Leu469 and
Glu382) that affected the affinity of -MrIA to inhibit [3H]NE
uptake through humanNET. Residues that increased theKd of a
tricyclic antidepressant (nisoxetine) were also identified
(Phe207, Ser225, His296, Thr381, and Asp473). Phe207, Ser225,
His296, and Thr381 also affected the rate of NE transport without
affecting NE Km. In a new model of NET constructed from the
bLeuT crystal structure, -MrIA-interacting residues were
located at the mouth of the transporter near residues affecting
the binding of small molecule inhibitors.
The monoamine neurotransmitter transporters are part of a
larger family of Na- and Cl-dependent transporters found in
bacteria through tomammals. Dopamine, serotonin, and nore-
pinephrine transporters (DAT,3 SERT and NET, respectively)
mediate the neuronal reuptake of their cognate neurotransmit-
ter substance, terminating neurotransmission. NET has been
implicated in mood states including depression and arousal, as
well as in the control of blood pressure and pain (1–5), and is
one of the targets of many psychoactive compounds including
stimulants and antidepressants. Precisely how these com-
pounds bind to NET is not well understood, but their interac-
tions appear distinct from those of norepinephrine (NE) (6–9).
Unlike NE, tricyclic antidepressants such as desipramine and
nisoxetine are not transported and appear to block by occluding
the pore of the transporter.
-MrIA is a peptide isolated from the venomof the predatory
marine snail Conus mamoreus (10). This conopeptide specifi-
cally inhibits NE transport by NETwithout affecting dopamine
or serotonin uptake by DAT and SERT, respectively (10, 11)
and suppresses neuropathic pain upon intrathecal administra-
tion to rodents (5).-MrIA is a non-competitive inhibitor ofNE
transport but a competitive inhibitor of tricyclic antidepres-
sants binding (11). Since desipramine and nisoxetine competi-
tively inhibit NE transport, it appears that the binding site of
-MrIA overlaps the antidepressant but not the NE binding
site.
There is currently no crystal structure of NET. Hence, struc-
tural details have been inferred from hydrophobicity, site-di-
rected mutagenesis (performed mostly on related DAT and
SERT proteins), and sequence analysis and subsequent com-
puter homology models based on related bacterial transporters
(12–19). NET and other monoamine neurotransmitter trans-
porters are predicted to have 12 membrane-spanning regions,
intracellular C and N termini, and a large extracellular loop
between transmembrane domains 3 and 4. A more detailed
view of monoamine transporters is starting to emerge with the
recent crystal structure of a bacterial leucine transporter
(bLeuT) (20), the closest functionally related transporter crys-
tallized to date. Like monoamine transporters, bLeuT is Na-
dependent with 12 membrane-spanning regions. bLeuT shares
28% identity with human NET (hNET) (see Fig. 1).
In the present study, we used a combination of site-directed
mutagenesis and homology modeling to locate residues on the
hNET that interact with -MrIA. In the process, we identified a
number of new interactions that affect NE transport and small
molecule antidepressant binding at hNET. These results sup-
port a new model of NET constructed from the bacterial
leucine transporter crystal structure.
EXPERIMENTAL PROCEDURES
Materials—Desipramine hydrochloride, dopamine hydro-
chloride, nisoxetine hydrochloride and ()-norepinephrine
bitartrate were obtained from Sigma. U-0521 and GBR-12909
dihydrochloride were from Biomol (Plymouth Meeting, PA).
levo-[ring,2,5,6-3H]Norepinephrine (specific activity: 57.9
Ci/mmol), [N-methyl-3H]nisoxetine hydrochloride (specific
activity: 85.0 Ci/mmol), and 3,4[ring-2,5,6-3H]dihydroxyphe-
nylethylamine (dopamine) (specific activity: 60 Ci/mmol) was
obtained from PerkinElmer Life Sciences.
Site-directed Mutagenesis—The QuikChange site-directed
mutagenesis kit (Stratagene, La Jolla, CA) was used with the
humanNET to producemutant cDNAs.Oligonucleotide prim-
ers were designed and obtained as custom syntheses (Proligo
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Australia Pty. Ltd., Lismore, Australia). Custom primers of
human NET were used to create the point mutants E122A,
L169T, N170E, D175A, G177N, H178N, K189H, N192D,
G193S, F207T, E223Q, S225H, H228D, L232P, Q234R, H296S,
D298A, E304A,D310A,D378A, T381K, E382A, A384P, E393A,
K463N, L469A, L469F, D473A, T474H, L543P, D546G, D547A,
P552D and W556A, and the double mutants L114S  L469F,
L232P L469F, and L469F L543P. F472L of the humanDAT
was also produced. A DAT loop 2 chimera was constructed by
using restriction sites for XhoI and SacII present in the large
extracellular loop of NET. The appropriate sequence of DAT
loop 2 was ligated into the NET (NET residues 166–210) and
site directed mutagenesis (Stratagene) was used to reorient a
frameshift that occurred during the ligation process. Sequenc-
ing was used to determine the correct orientation of the EL2
chimera. Escherichia coliwere transformedwithmutant cDNA
and subsequently used for plasmid preparation using aWizard
SV plasmid preparation kit (Beckman Coulter Australia Pty.
Ltd., Gladesville, Australia) or a Qiagen mini preparation kit
(Qiagen Pty. Ltd., Doncaster, Australia). Samples of purified
mutant cDNAwere prepared for automatic sequencing using a
Big-Dye Terminator kit (Applied Biosystems,Melbourne, Aus-
tralia), with custom synthesized sequencing primers (Invitro-
gen or Sigma-Aldrich) and the cDNA from plasmid prepara-
tions. Samples were sent to the Australian Genome Research
Facility (University of Queensland, Queensland, Australia) for
automated sequencing to confirm each mutation.
Cellular Uptake of [3H]Norepinephrine, [3H]Dopamine, and
Binding of [3H]Nisoxetine—Cellular accumulation ofNE, dopa-
mine, and determination of inhibitor IC50 values were per-
formed in 24-well plates as described previously (11) or for
norepinephrine uptake and nisoxetine binding assays in amod-
ified 96-well plate assay. Briefly, COS-1 cells (ATCC;Manassas,
VA) were grown in 96-well plates (Nunclon; Nalge Nunc Inter-
national, Rochester, NY) containing Dulbecco’s modified
Eagle’s medium (Invitrogen) and 10% fetal bovine serum
(Invitrogen) at 37 °C in 5% CO2. The cells were transiently
transfected with purified plasmid DNA encoding the human
NET (hNET) (12) or mutant NETs using Metafectene reagent
(Biontex Laboratories GmbH, Munich, Germany). Assays
measuring uptake were performed 48 h after transfection at
room temperature. The culture medium was removed and the
cells were gently washed three times with 150 l of transport
buffer containing 125 mM NaCl, 4.8 mM KCl, 1.2 mM MgSO4,
1.2 mMKH2PO4, 1.3 mMCaCl2, 25 mMHEPES, 5.55 mM D-()-
glucose, 1.0 mM ascorbic acid, 0.1% bovine serum albumin, 10
M U-0521 (to inhibit catechol-O-methyltransferase) and 100
M pargyline (to inhibit monoamine oxidase) at pH 7.4. The
final reaction volume was 50 l. Nonspecific uptake of [3H]NE
by transfected cells was defined by the accumulation occurring
in the presence of 100 M desipramine or 100 M nisoxetine.
Transfected cells were exposed to [3H]NE for 5–8min at room
temperature. The solution containing free [3H]NE was then
rapidly removed, and the cells washed three times with 200 l
of ice-cold transport bufferwithout bovine serumalbumin. The
cells were lysed with 50 l 0.1 M NaOH at room temperature
with gentle shaking. 30 l of the cell lysate was used to deter-
mine the level of radioactivity by liquid scintillation counting
and the remaining 20 l was used for protein determination.
Triplicate measures were made for each experiment (n  3–8
experiments). Specific uptake of [3H]NE was defined as the dif-
ference between total uptake and that occurring in the presence
of 100 M desipramine or 100 M nisoxetine.
Assays measuring [3H]nisoxetine binding were performed
48 h after transfection on whole cells. Cells were trypsinized
from standard plasticware and counted using a hemocytometer
and diluted to give 50,000 cells per well. Cells were added to
96-well plates containing binding buffer (transport buffer at
0 °C) with appropriate compounds. Final assay volume was 50
l. Nonspecific binding of [3H]nisoxetine by transfected cells
was determined in the presence of 200 M dopamine. Trans-
fected cells were exposed to [3H]nisoxetine for 60 min at 0 °C.
Bound and free radioactivity were separated by rapid vacuum
filtration onto GF/B filters (Whatman, Boston, MA) pretreated
with 0.6% polyethylenimine. Filters were washed three times
with ice-cold phosphate-buffered saline and dried. Filter-re-
tained radioactivitywas quantified by liquid scintillation count-
ing. Triplicate measures were made for each experiment (n 
2–6 experiments).
Homology Modeling—The FASTA format of the hNET and
bLeuT sequences were retrieved and alignments made using
the alignments of prokaryotic and eukaryotic Na dependent
transporters developed by Beuming et al. (21), with additional
manual adjustments specific for monoamine transporters (see
Fig. 1B). The leucine transporter crystal structure (ProteinData
Bank code 2A65) was loaded in the INSIGHT II (Accelrys, San
Diego, CA) environment and used as a template. Ten homology
models of the NET based on our sequence alignment was built
on a Silicon Graphics Octane R120000 work station using the
MODELLER program (22). N and C termini were not included
in themodel building process. Themost energetically favorable
model was chosen for analysis and to produce the figures. The
water accessible path (Fig. 6) was calculated using the CAVER
program (23) and rendered with PyMOL.
Statistics andDataAnalysis—Data are expressed asmeans
S.E. (or 95% confidence interval range) of averaged results
obtained from 2–8 separate experiments. Either analysis of
variance with post hoc t-tests performed by the Tukey method
or Student’s t tests were used to evaluate the statistical signifi-
cance of differences between groups. Values of p  0.05 were
FIGURE1.A, topologicalmapof theNETproteinbuilt fromthebLeuT (ProteinDataBank code2A65) (20). Transmembranehelices are shownas stacked residues
and are numbered 1–12 in light blue. Helical features are based on the homology model of the crystal structure of bLeuT (20). The C and N termini are
intracellular and extracellular loops are labeled dark red. Filled circles indicate the residues mutated in this study. Red filled residues designate residues
important forMrIA binding. B, sequence alignments of humanNET, DAT, SERT, and bLeuT (20) were as described by Beuming et al. (21) andmanual alignment
(black lines above sequences). An automated alignment built in Insight II (Accelerys, San Diego, CA) produced a comparable result. Transmembrane helical
motifs are highlighted in light blue and labeled and additional helical motifs are colored purple. Residues highlighted with the same color indicate conserved
and partially conserved residues. The asterisks indicate the individual residues mutated in this study. The red underlined region indicates an EL2 chimera
constructed by inserting the corresponding section DAT into NET.
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FIGURE 2. Effect of NETmutants on the IC50 ofMrIA anddesipramine inhibition of [
3H]NE uptake. A and B, representative concentration-response curves
for MrIA (A) or DMI at selectedmutants (B). COS-1 cells transiently transfected with wild-type (F with solid lines) or mutant NETs (dotted lines) and inhibition of
NE uptake for E382A (‚), L469F (), L114S L469F (E), L232P L469F (), or L469F L543P (ƒ) by MrIA or desipramine. Each data set was normalized to
transport in the absence ofMrIA. Curves were obtained by non-linear regression analyses based on a sigmoidal model. Nonspecific uptakewas determined in
the presence of desipramine (104 M) for thewild-type andmutantNETs.C andD, comparison of pIC50 values ofmutantNETs determined from inhibition of NE
uptake by eitherMrIA (C) or desipramine (D). All mutants produced for this study are shown, except where NE uptakewas unable to be determined. Values are
means S.E. of 2–3 separate experiments each performed in triplicate.
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considered significant. Curve fitting of saturation binding,
transport kinetic and concentration-response data were per-
formed by non-linear regression using Prism 4.0 software
(GraphPad, San Diego, CA).
RESULTS
Construction of hNET Mutants—To further investigate the
residues involved in MrIA inhibition of NE uptake, mutations
of hNET were made by introducing DAT residues into regions
of difference. All the mutated NETs (Fig. 1) were confirmed by
sequence analysis before transient transfection into COS-1
cells. All NETmutations, except F207T, S225H,H296S, T381K,
and D473A, produced uptake of [3H]NE that was not signifi-
cantly different from uptake by wild-type NET and susceptible
to inhibition by desipramine (DMI). Specific uptake for wild-
type NET under these experimental conditions was 1.776 
0.35 pmol/mg of protein/min (n 8).
Inhibition of [3H]NEUptake byMrIAandDMIat Single Point
Mutants of hNET—Mutations of hNET that produced readily
measurable [3H]NE uptake were assessed for susceptibility to
MrIA and desipramine inhibition (Fig. 2). Concentration-re-
sponse curves for NETmutants affecting IC50 of MrIA or DMI
are shown in Fig. 2,A and B, respectively. The pIC50 (logIC50)
values for MrIA and DMI at each mutation are shown in Fig. 2,
C and D, respectively. These studies reveal that single residue
changes at position 382 (E382A) significantly reduced (8.3-fold)
the IC50 ofMrIA for theNET comparedwithwild type (Fig. 2C)
without affecting DMI inhibition. Conversely, a single change
at position 469 (L469F) significantly increased (88-fold) the
IC50 ofMrIA for inhibition of the NET (Fig. 2C) without affect-
ing DMI inhibition. The reverse mutation of DAT, F472L, con-
ferredMrIA sensitivity which was significant at the mutant but
not at the wild type DAT in dopamine uptake assays (mutant
pIC50  3.70  0.13; n  3). In contrast, the pIC50 values for
DMI inhibition of [3H]NE uptake were not affected by any of
these single pointmutations (Fig. 2D). In addition, 3.9–4.3-fold
increases in IC50 approaching significance (p 0.054 by t test)
were observed for bothMrIA and DMI at the L232P and L543P
mutants (Fig. 2, C and D), suggesting a potential overlap of
MrIA and DMI binding sites on NET.
Double Mutations and Chimera of hNET—Due to the
marked effect of L469F on the pIC50 value forMrIA, the double
mutants L232P  L469F and L469F  L543P of hNET were
constructed to determine the extent of any interactions
between these positions (Fig. 2). The double mutant L114S 
L469F of hNETwas also assessed (Fig. 2), since L114S increased
MrIA and DMI IC50 values3-fold (24). All double mutations
gave IC50 values for MrIA inhibition of [3H]NE uptake that
were significantly increased compared with the hNET value
(Fig. 2, A and C) but not significantly different to the single
mutant value for L469F, indicating there was no additive effect.
L114S  L469F also significantly increased (30-fold) the IC50
value of DMI for inhibition of [3H]NE uptake (Fig. 2D). The
other double mutants L232P  L469F and L469F  L543P
FIGURE 3. Saturation binding of [3H]nisoxetine at hNET and mutants
showing poor [3H]NE uptake. COS-1 cells transiently transfectedwith hNET
(F) ormutantNETs; F207T (E), S225H (), H296S (), T381K (‚), orD473A (ƒ)
were incubated for 60min at 0 °Cwith increasing concentrationsof [3H]nisox-
etine. Each point is the mean  95% confidence interval determined from
3–6 experiments each performed in triplicate. The curves were obtained by
non-linear regression analyses according to a hyperbolic model. Specific
bindingwas calculated as thedifferencebetweenbinding in the absence and
presence of 200 M dopamine.
FIGURE 4. Saturation of [3H]NE uptake by mutants with poor [3H]NE
uptake. COS-1 cells transiently transfected with hNET (F) or mutant NETs
F207T (‚), S225H (), H296S (), T381K (E), or D473A (ƒ) were incubated for
5 min at room temperature with increasing concentrations of [3H]NE. Each
point is the mean  95% confidence interval determined from three to six
experiments each performed in triplicate. The curves were obtained by non-
linear regression analyses according to a hyperbolic model. Specific uptake
was calculatedas thedifferencebetweenuptake in theabsenceandpresence
of 100 M nisoxetine.
TABLE 1
3HNE transport and 3Hnisoxetine binding at hNET and selected mutants
3HNE, Km Normalized 3HNE, Vmax 3HNisoxetine Kd Normalized 3Hnisoxetine, Bmax
nM nM
hNETa 690 (320, 1490)b 1.0 5.1 (2.3, 11)b 1.0
F207T 720 (260, 1930) 0.26 (0.1, 0.7)c 319 (81, 1260)c 0.60 (0.1, 2.6)
S225H 1870 (157, 6966) 0.31 (0.1, 0.9)c 656 (194, 1120)c 1.1 (0.6, 1.5)
H296S 1190 (200, 7160) 0.25 (0.1, 0.6)c 257 (62, 1070)c 0.66 (0.3, 1.4)
T381K 530 (190, 1480) 0.17 (0.1, 0.3)c 650 (156, 2720)c 0.82 (0.3, 2.5)
D473A 1580 (400, 6280) 0.26 (0.1, 0.5)c 47 (17, 130)c 0.19 (0.1, 0.7)a
aVmax for hNET 1.776 0.35 pmol/mg of protein/min; Bmax for hNET 129.5 14.5 pmol/mg of protein (n 8 experiments).
b 95% confidence interval values shown in parentheses (n 3–8 experiments).
c Significantly different from wild-type hNET.
NewNorepinephrine Transporter Model
JUNE 15, 2007•VOLUME 282•NUMBER 24 JOURNAL OF BIOLOGICAL CHEMISTRY 17841
caused small increases (3-fold, which was not significant)
in the IC50 value of DMI (Fig. 2D), similar to the increase
seen previously for L114S alone (24). The EL2 chimera did
not significantly affect the ability of DMI (pIC50 9.13 0.12)
or MrIA (pIC50 6.8  0.12) to inhibit NE uptake in this
mutant.
hNET Mutants with Poor Specific Uptake of [3H]NE—In our
initial studies, the F207T, S225H, H296S, T381K, and D473A
mutants of hNET failed to show significant [3H]NE uptake.
Lack of apparent [3H]NE uptake could arise from (i) a marked
reduction in cell surface expression of protein (for example as a
result of protein misfolding), (ii) a marked reduction in the
affinity of NE for the transporter,
and/or (iii) effects on the transloca-
tion or gating mechanism of NET.
To establish if NET expression was
affected, we determined the Bmax
andKd for [3H]nisoxetine binding to
these mutants (Fig. 3). Bmax (maxi-
mal binding) has been shown previ-
ously to provide a good measure of
surface expression (25). Using a
similar approach, F207T, T381K,
S225H, and H296S produced maxi-
mal binding that was not signifi-
cantly different to wild-type hNET,
while D473A produced20% wild-
type binding (Fig. 3 and Table 1).
F207T, T381K, S225H, and H296S
also significantly increased (30–130-
fold) the Kd for [3H]nisoxetine com-
pared with hNET, while the D473A
mutant produced a 9-fold increase
in Kd (Table 1). Since specific
[3H]nisoxetine binding was detecta-
ble for all mutants, we reassessed
their ability to transport [3H]NE
using higher NE substrate concen-
trations (Fig. 4). Under these condi-
tions, all mutants displayedmeasur-
able uptake of [3H]NE (Fig. 4), with
maximal uptake reduced 3–6-fold
compared with hNET (Table 1 and
Fig. 4). The Km of NE for these
mutants was not significantly
altered despite the Kd of [3H]nisox-
etine being dramatically affected
(Table 1, Fig. 4). Unfortunately,
assays measuring specific [3H]NE
uptake or specific [3H]nisoxetine
binding had poor signal to noise and
we were unable to measure the IC50
of MrIA at these mutants using
these assays.
Homology Model of the hNET—A
homology model of the hNET was
constructed using bLeuT as a tem-
plate (Fig. 5). The structure main-
tains 12 membrane spanning helices (TM) as previously pre-
dicted by hydrophobicity analysis (12). As defined by bLeuT,
the majority of the helices are not perpendicular to the lipid
bilayer but angled to form a pore with a wide external mouth
and associated gating structure (including elements from
EL2 and EL4). This architecture uses helices of widely vary-
ing lengths (Figs. 1A and 5) including several amphipathic
helices (TM3, TM8, and TM10) exposed on the extracellular
surface and potentially lying along the top of the lipid bilayer
(extracellular loops EL3 and EL6) and helices potentially lin-
ing a water-filled translocation pathway (TM1 and TM6)
(Fig. 5). Amino acid residues influencing the affinity of the
FIGURE5.Homologymodel of theNETprotein constructed fromthe crystal structureof theNa-dependent
bLeuT(20).Helical structuresareshowninred.Top(A)andside(B)viewsofNETshowingresiduesthataffectedMrIA
affinity (Leu114 (24),Leu232,Glu382,Leu469,andLeu543 inblue). Top(C)andside(D)viewsofNETshowingresiduesthat
affected [3H]nisoxetine affinity (Leu114 (24), Phe207, Ser225, His296, Phe316 (28), Thr381, andAsp473 ingray). Leu469 also
reduced the affinity of [3H]nisoxetine as the doublemutantwith Leu114.
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transporter for MrIA (Fig. 5, A and B) and nisoxetine (Fig. 5,
C and D) are highlighted.
DISCUSSION
Using site-directed mutagenesis to introduce DAT residues
into human NET (Fig. 1), we have identified new positions
affecting -MrIA (L469F) and tricyclic antidepressant (F207T,
T381K, S225H, and H296S) binding to NET. An additional
eight NET mutants with negatively charged residues predicted
to lie in extracellular loops replaced with alanine also identified
a potential MrIA clash (E382A) and an additional contributor
to tricyclic binding (D473A). To start to understand how these
mutants affected inhibitor interactions with NET, we con-
structed a homology model of NET (Figs. 5 and 6) from the
bLeuT structure, the closest related Na-dependent trans-
porter crystallised (20). Examination of thismodel revealed that
most of the interacting residues identified in this study clustered
near the predicted entrance for NE transport (Fig. 5), providing
experimental support for the bLeuT-derivedmodel of NET.
Of the 33 positions examined, E382A enhanced (8-fold) and
L469F reduced (88-fold) the affinity of MrIA to inhibit NE
uptake by hNET. Given the predicted position of Glu382 in the
mouth of NET (Figs. 5A and 6), its charge and/or size might
possibly hinder MrIA binding. In a previous alanine scan of
MrIA, four residues (Tyr7, Lys8, Leu9, and His11) were identi-
fied as contributing directly to MrIA inhibition of NET trans-
port (11). Given the negative effect of Glu382 on MrIA binding
and the lack of effect of replacing other negative charges in the
extracellular loops, potential salt bridges betweenNET residues
and the Lys8 or His11 of MrIA do not appear to contribute to
affinity. Leu469 is situated at the
mouth of NET in close proximity to
Glu382 (C–C distance: 15 Å).
However, in this instance replacing
it with the corresponding DAT res-
idue (Phe) markedly reduced the
affinity of MrIA to inhibit NE
uptake. Likewise, changing Phe472
of DAT to the NET residue leucine
made the DAT sensitive to MrIA
inhibition, confirming that this res-
idue has an important influence on
MrIA affinity. Since the L469A
mutant had no effect on MrIA inhi-
bition, it appears that smaller
hydrophobic residues at this posi-
tion support high affinity MrIA
binding and that the hydrophobic
and bulky Phe interferes with MrIA
binding, presumably due to a steric
clash. The small increases in IC50 of
MrIA at the L232P and L543P
mutants, which approached signifi-
cance in these studies, may arise
from structural perturbations asso-
ciated with the introduction of Pro
(26, 27). According to the homology
model, these residues are in external
loops on opposite sides of NET where they could influence the
conformation of the mouth of NET. Double mutants of these
residues together with L469F did not have any additional
impact on MrIA affinity, indicating that any effect of these
residues was relatively minor. In a previous study, residue
L114A and L114S mutants reduced MrIA, antidepressant
(desipramine) and cocaine affinity to similar extents (3–10-
fold) (24). In the present study, the L469F  L114S double
mutant did not show any additive effects on MrIA IC50.
In contrast to MrIA, none of the single point mutations of
hNETdescribed above affected desipramine IC50.However, the
L469F  L114S double mutant caused a 32-fold increase in
desipramine IC50, 5-fold greater than seen for the single L114S
mutation alone (24). After examination of the homologymodel,
it is apparent that L114 is positioned intracellularly, where it is
unlikely to have any direct interaction with either substrates or
inhibitors. Hence it is most likely that the L114S mutation
introduces a structural change or conformational shift in NET,
as suspected from its similar effect on IC50 across a range of
unrelated inhibitors (24). Apparently, this mutation exposes an
otherwise silent effect of L469F, to further increase the IC50 for
desipramine. The chimera of extracellular loop 2 of DAT and
NEThadno effect onDMIorMrIA inhibition ofNEuptake and
is unlikely to be involved in the binding of either inhibitor.
Of the hNET mutants constructed, F207T, S225H, H296S,
and T381K showed poor NE uptake despite normal nisox-
etine Bmax values, indicating that the rate of NE transport
was diminished while surface expression remained
unchanged (NET turnover (Vmax(NE)/Bmax(nisoxetine)) was
reduced 2.3–5-fold). The other poor transporter D473A had a
FIGURE 6. Proposed binding positions of MrIA, the tricyclic DMI, and NE at NET. The homology model of
human NET in ribbon representation (from Fig. 5) shows the presumed water-filled pathway (gray volume)
linking the extracellular space to the substrate binding site (calculatedusingCAVER (23)). Residueswith largest
effect on MrIA binding (Glu382 and Leu469) are shown in Corey-Pauling-Koltun representation. MrIA, DMI, and
NE are shown in stick and transparentmolecular surface rendition at the same scale asNET. Vertical positions of
MrIA,DMI, andNE in theporeofNETare shown relative to the sideviewofNET (left panel).Right panel shows the
top (90° rotated) view of left panel. Overlap apparent between MrIA/DMI and DMI/NE but not MrIA/NE is
consistent with the competitive MrIA/DMI and DMI/NE interactions and the noncompetitive MrIA/NE interac-
tion (11).
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5-fold reduced Bmax, indicating expression levels for this
mutant were reduced (24), accounting for the reduced NE
transport observed. While these mutants had no effect on Km
value of NE, they had a dramatic effect on nisoxetineKd. Muta-
tions affecting transport rate (F207T, T381K, S225H, and
H296S) caused a 30–130-fold reduction in [3H]nisoxetine
affinity, while the D473A mutant caused a smaller (9-fold)
reduction. Examining the homologymodel revealed that all res-
idues affecting NE transport and nisoxetine affinity were
located at the ends of extracellular helices that either lined
(Thr381 and Asp473) or were just outside (Phe207, Ser225, and
His296) the mouth of the transporter. While residues lining the
mouth of NET could directly influence both affinity and trans-
port, mutations outside the mouth might be expected to indi-
rectly reduce affinity and transport by disrupting the structure
and/or gating of NET. Unfortunately, we were unable to assess
the IC50 ofMrIA at thesemutants. Earlier studies identified two
mutations that caused 6-fold shifts in the IC50 of DMI to inhibit
NE uptake (28), Phe316, which appears near the center of the
transporter, and Leu114, which is located intracellularly (Fig. 5).
Previousmodels of the dopamine and serotonin transporters
(15, 17, 29, 30) were based on functionally unrelated transport-
ers such as the sodiumhydrogen antiporter (NhaA transporter)
(31), glutamate (16), and Lac permease (32) transporters.While
these models incorporated mutagenesis and biochemical data,
the templates had lowhomology (12%) and limited functional
similarity. In contrast, hNET and bLeuT have 28% sequence
homology and both are Na-dependent transporters and thus
expected to share secondary, tertiary, and quaternary structure.
A similar level of homology between the functionally related
nicotinic acetylcholine receptor and the molluscan acetylcho-
line-binding protein allows the production of predictive
homology models of the nicotinic acetylcholine receptor (33).
The newmodel of NET shows a tapered water-filled cavity that
restricts intracellular access and several external helical loops
positioned around the mouth of the pore that could influence
ligand binding (Fig. 6). The deepest portion of this cavity allows
the binding of NE at the same location as the leucine seen in
bLeuT. Consistent with results of our previous studies (11), the
model allows partially overlapping MrIA/tricyclic binding and
tricyclic/NE binding but discrete MrIA/NE binding. It is also
consistent with previous NET mutant data (6, 28, 34). This
model should prove useful in guiding the design of improved
inhibitors of NET.
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